Representative Schlegel told the committee HB 36 strengthens the state's Drug Dealer Liability Act to apply to consumable hemp products sold outside Louisiana’s regulatory framework and to create civil liability when such products are sold to under-21 buyers.

"This bill simply clarifies that this act applies to those who choose to operate outside the narrow legal pathway we've carved out for consumable hemp," Schlegel said, emphasizing the law is not intended to ban regulated hemp products.

Dr. Joseph (Joey) Jones, forensic toxicologist and system director for the North Louisiana Forensic Lab in Shreveport, testified the American Psychiatric Association opposes cannabis use for individuals under 25 and warned that adolescent cannabis exposure can increase risk of anxiety, depression and psychosis. He also cited rising unregulated-product poisonings and mislabeling.

The committee adopted amendment set 13 19, which clarified technical definitions and changed the civil-action age provision from "minor" to a person under age 21 so the cause of action covers those not permitted to purchase consumable hemp despite not technically being minors under civil-code definitions.

Opponents noted potential interstate-commerce conflicts and enforcement challenges when products legally sold in other states differ from Louisiana’s labeling and testing requirements. A licensed hemp grower said inconsistent testing and packaging across states could create uncertainty for ordinary purchasers and sellers. Representative Schlegel said the bill targets sellers operating outside Louisiana’s rules and is limited to civil remedies for harms arising from unregulated sale.

The committee adopted the amendments and reported HB 36 with amendments.

Votes at a glance: Amendment set 13 19 adopted; HB 36 reported out of committee with amendments.